Pfizer INC DEF 14A proxy statements

Pfizer Inc. has filed a Definitive Proxy Statement (DEFA14A) with the SEC, signaling upcoming shareholder matters.

Pfizer reported a 2% operational revenue decline in 2025 but highlighted 6% ex-COVID growth, significant cost savings, and strategic pipeline advancements, while addressing executive compensation concerns.

Pfizer's Annual Meeting of Shareholders will be held virtually on April 24, 2025, with the Board recommending votes for director nominees, ratification of KPMG LLP, advisory approval of executive compensation, and against two shareholder proposals.

Pfizer Inc. will hold its 2025 Annual Meeting of Shareholders virtually on April 24, 2025, and has provided information on how to learn more and vote.

Pfizer Inc. disseminates its proxy statement via LinkedIn, Facebook, Yahoo! Finance, display advertising, and Google Search Advertising on April 10, 2025.

Pfizer announces its virtual annual meeting and highlights a year of transformative change and innovation in 2024, with a focus on R&D realignment and shareholder value.

Pfizer's supplemental proxy material details executive compensation, long-term incentive award modifications, and key performance metrics for 2024, alongside strategic achievements and shareholder proposals.

Pfizer Inc. has filed a definitive proxy statement with the SEC.

Pfizer's 2025 proxy statement outlines key governance matters, including director elections, executive compensation, and shareholder proposals, highlighting the company's performance and strategic priorities.

Pfizer Inc. has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.

Pfizer Inc. has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.

Pfizer Inc. has filed a definitive proxy statement with the SEC, indicating upcoming shareholder meetings and voting matters.

Pfizer Inc. has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.

Pfizer is seeking shareholder approval for an amended and restated version of its 2019 Stock Plan at the upcoming Annual Meeting on April 25, 2024.

A shareholder proposal regarding director resignation processes has been withdrawn from Pfizer's upcoming Annual Meeting of Shareholders.

Pfizer Inc. has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.

Pfizer's 2024 proxy statement outlines the company's performance in 2023, executive compensation, and key proposals for the upcoming annual meeting.